{"created":"2023-06-19T07:25:17.939190+00:00","id":12981,"links":{},"metadata":{"_buckets":{"deposit":"8185f936-5cbc-461f-9b5b-2b36b381477a"},"_deposit":{"created_by":4,"id":"12981","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"12981"},"status":"published"},"_oai":{"id":"oai:gifu-pu.repo.nii.ac.jp:00012981","sets":["147:220"]},"author_link":["18112","18119","18114","18109","18116","18111","18108","18115","18118","18110","18113","18117"],"item_1_biblio_info_14":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2014-06-30","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"21","bibliographicPageStart":"11","bibliographicVolumeNumber":"63","bibliographic_titles":[{"bibliographic_title":"岐阜薬科大学紀要　"},{"bibliographic_title":"The annual proceedings of Gifu Pharmaceutical University","bibliographic_titleLang":"en"}]}]},"item_1_creator_6":{"attribute_name":"著者名(日)","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"田中, 彦孝"}],"nameIdentifiers":[{"nameIdentifier":"18108","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鶴間, 一寛"}],"nameIdentifiers":[{"nameIdentifier":"18109","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"嶋澤, 雅光"}],"nameIdentifiers":[{"nameIdentifier":"18110","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"原, 英彰"}],"nameIdentifiers":[{"nameIdentifier":"18111","nameIdentifierScheme":"WEKO"}]}]},"item_1_creator_7":{"attribute_name":"著者名よみ","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"タナカ, ヒロタカ"}],"nameIdentifiers":[{"nameIdentifier":"18112","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"ツルマ, カズヒロ"}],"nameIdentifiers":[{"nameIdentifier":"18113","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"シマザワ, マサミツ"}],"nameIdentifiers":[{"nameIdentifier":"18114","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"ハラ, ヒデアキ"}],"nameIdentifiers":[{"nameIdentifier":"18115","nameIdentifierScheme":"WEKO"}]}]},"item_1_creator_8":{"attribute_name":"著者名(英)","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"TANAKA, Hirotaka","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"18116","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"TSURUMA, Kazuhiro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"18117","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"SHIMAZAWA, Masamitsu","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"18118","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"HARA, Hideaki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"18119","nameIdentifierScheme":"WEKO"}]}]},"item_1_description_1":{"attribute_name":"ページ属性","attribute_value_mlt":[{"subitem_description":"P(論文)","subitem_description_type":"Other"}]},"item_1_description_11":{"attribute_name":"抄録(日)","attribute_value_mlt":[{"subitem_description":"筋萎縮性側索硬化症(ALS) は上位および下位運動ニューロンが選択的かつ進行性に変性、脱落する重篤な指定神\n経難病である。長年、ALS に対する精力的な研究が行われてきたが、現時点でALS 病態の原因は不明である。本試験に\nおいて、変異Cu/Zn superoxide dismutase (SOD1G93A) 発現ALS モデルマウスを用いたDNA マイクロアレイ解析を実施し\nたところ、glycoprotein nonmetastatic melanoma protein B (GPNMB) が新規 ALS 病態関連因子として同定された。ALS 患者\nおよびALS モデルマウス脊髄において病態の進行に伴うGPNMB の顕著な増加が認められた。また、GPNMB の発現は、\n運動ニューロンおよびアストロサイトにおいて認められた。さらに、運動ニューロン様細胞であるNSC34 細胞株を用い\nた検討により、SOD1G93AがGPNMBと結合しGPNMBの糖鎖修飾を阻害することで運動ニューロンの脆弱性が亢進した。\n一方、活性化したアストロサイトでは、GPNMB細胞外断片の分泌が認められ、その結果運動ニューロンに対するSOD1G93A\n毒性を減弱させた。さらに、ALS 患者血清中のGPNMB 量は、コントロール群および他の中枢神経変性疾患群に比べ高\n値を示した。以上より、GPNMB は、ALS の有用な治療標的となる可能性が示唆された。","subitem_description_type":"Other"}]},"item_1_description_12":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_description":"Amyotrophic lateral sclerosis (ALS) is an incurable and fatal neurodegenerative disease characterized by the loss of motor\nneurons. Despite substantial research, the causes of ALS remain unclear. Glycoprotein nonmetastatic melanoma protein B (GPNMB)\nwas identified as an ALS-related factor using DNA microarray analysis with mutant superoxide dismutase (SOD1G93A) mice.\nGPNMB was greatly induced in the spinal cords of ALS patients and a mouse model as the disease progressed. It was especially\nexpressed in motor neurons and astrocytes. In a NSC34 cell line, glycosylation of GPNMB was inhibited by interaction with\nSOD1G93A, increasing motor neuron vulnerability, whereas extracellular fragments of GPNMB secreted from activated astrocytes\nattenuated the neurotoxicity of SOD1G93A in neural cells. Furthermore, GPNMB expression was more substantial in the sera of\nsporadic ALS patients than in other diseased patients. This study suggests that GPNMB can be a target for therapeutic intervention\nfor suppressing motor neuron degeneration in ALS.","subitem_description_type":"Other"}]},"item_1_source_id_13":{"attribute_name":"雑誌書誌ID","attribute_value_mlt":[{"subitem_source_identifier":"AA1258935X","subitem_source_identifier_type":"NCID"}]},"item_1_text_10":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Department of Biofunctional Evaluation, Molecular Pharmacology, Gifu Pharmaceutical University"}]},"item_1_text_2":{"attribute_name":"記事種別(日)","attribute_value_mlt":[{"subitem_text_value":"総説"}]},"item_1_text_3":{"attribute_name":"記事種別(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Review"}]},"item_1_text_9":{"attribute_name":"著者所属(日)","attribute_value_mlt":[{"subitem_text_value":"岐阜薬科大学生体機能解析学大講座 薬効解析学研究室"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2014-08-06"}],"displaytype":"detail","filename":"膜貫通糖タンパク質GPNMB のALS 病態に対する神経保護因子としての可能性.pdf","filesize":[{"value":"1.1 MB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"膜貫通糖タンパク質GPNMB のALS 病態に対する神経保護因子としての可能性","url":"https://gifu-pu.repo.nii.ac.jp/record/12981/files/膜貫通糖タンパク質GPNMB のALS 病態に対する神経保護因子としての可能性.pdf"},"version_id":"6c2c82fa-3193-4fe1-bb3d-9a7e91dfc7c1"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"筋萎縮性側索硬化症","subitem_subject_scheme":"Other"},{"subitem_subject":"膜貫通糖タンパク質GPNMB","subitem_subject_scheme":"Other"},{"subitem_subject":"運動ニューロン死","subitem_subject_scheme":"Other"},{"subitem_subject":"amyotrophic lateral sclerosis","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"glycoprotein nonmetastatic melanoma protein B","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"motor neuron death","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"膜貫通糖タンパク質GPNMB のALS 病態に対する神経保護因子としての可能性","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"膜貫通糖タンパク質GPNMB のALS 病態に対する神経保護因子としての可能性"},{"subitem_title":"The Potential of GPNMB as a Novel Neuroprotective Factor in Amyotrophic Lateral Sclerosis","subitem_title_language":"en"}]},"item_type_id":"1","owner":"4","path":["220"],"pubdate":{"attribute_name":"公開日","attribute_value":"2014-08-06"},"publish_date":"2014-08-06","publish_status":"0","recid":"12981","relation_version_is_last":true,"title":["膜貫通糖タンパク質GPNMB のALS 病態に対する神経保護因子としての可能性"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2023-06-19T09:01:09.544531+00:00"}